Rockefeller Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Rockefeller Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,534	Closed	-$666K	–	1871
2023 Q2	$666K	Buy	6,534 +60	+0.9%	+$5.68K	﹤0.01%	1238
2023 Q1	$588K	Hold	6,474	–	–	﹤0.01%	1284
2022 Q4	$245K	Buy	6,474 +950	+17%	+$32.7K	﹤0.01%	1572
2022 Q3	$138K	Sell	5,524 -768	-12%	-$21.3K	﹤0.01%	1826
2022 Q2	$191K	Buy	6,292 +168	+3%	+$5.01K	﹤0.01%	1658
2022 Q1	$200K	Buy	6,124 +4,874	+390%	+$145K	﹤0.01%	1693
2021 Q4	$32K	Sell	1,250 -2,189	-64%	-$169K	﹤0.01%	2416
2021 Q3	$345K	Sell	3,439 -969	-22%	-$114K	﹤0.01%	1392
2021 Q2	$623K	Buy	4,408 +2,708	+159%	+$306K	﹤0.01%	1101
2021 Q1	$169K	Hold	1,700	–	–	﹤0.01%	1384
2020 Q4	$210K	Sell	1,700 -43	-2%	-$5.65K	﹤0.01%	1179
2020 Q3	$169K	Buy	1,743 +1,718	+6,872%	+$215K	﹤0.01%	1098
2020 Q2	$4K	Sell	25 -16	-39%	-$2.43K	﹤0.01%	2187
2020 Q1	$6K	Sell	41 -9	-18%	-$1.74K	﹤0.01%	1922
2019 Q4	$10K	Hold	50	–	–	﹤0.01%	1624
2019 Q3	$4K	Buy	+50	New	+$4.24K	﹤0.01%	1705

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Rockefeller Capital Management's RETA Position: Q3 2023 in Review

Rockefeller Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 6,534 shares — an estimated $666K sold.

Rockefeller Capital Management first reported a position in RETA in Q3 2019 and held it in 16 quarters. The position peaked at $666K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Rockefeller Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Rockefeller Capital Management sold 6,534 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $666K.
Rockefeller Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2019 and held it in 16 quarters.
Rockefeller Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $666K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Rockefeller Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.